ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Sep 10, 2024 · CIK: 1715925
Sentiment: neutral
Topics: reporting, press-release
TL;DR
IPA files 6-K with press release, check Exhibit 99.1 for details.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on September 10, 2024, reporting a press release dated September 9, 2024. The filing is for the month of September 2024 and indicates the company will file annual reports under Form 20-F. The press release itself is included as Exhibit 99.1.
Why It Matters
This filing provides an update on ImmunoPrecise Antibodies Ltd.'s reporting status and includes a press release, which may contain material business developments.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily includes a press release and confirms reporting status, with no immediate financial or operational disclosures that suggest high risk.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the 6-K report
- September 9, 2024 (date) — Date of the press release
- September 10, 2024 (date) — Filing date of the 6-K report
- Kristin Taylor (person) — Signatory for the filing
- Exhibit 99.1 (document) — Press Release included in the filing
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of September 2024, and includes a press release dated September 9, 2024.
Which exhibit contains the press release?
Exhibit 99.1 contains the Press Release dated September 9, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Will ImmunoPrecise Antibodies Ltd. file annual reports under Form 20-F or Form 40-F?
The registrant indicates it files or will file annual reports under cover of Form 20-F.
Who signed the filing on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor signed the filing on behalf of ImmunoPrecise Antibodies Ltd.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-09-09 17:34:56
Filing Documents
- press_release_sept_9_202.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 21KB
- 0000950170-24-104823.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: September 9, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer